AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Orthocell (OCC) completes first US surgery using Remplir
- Remplir targets $2.4B US nerve repair market
- Distributor-led expansion fuels growth momentum
Orthocell (ASX:OCC), a regenerative medicine company, has taken a critical step forward in its international commercialisation journey with the first successful surgical use of its nerve repair product, Remplir, in the United States. This achievement underscores Orthocell’s growing momentum in the global peripheral nerve repair market, which is valued at over US$5.3 billion.
The surgery, performed in Ohio, marked the first time Remplir has been used clinically in the US following recent regulatory clearance. This procedure targeted the repair of a foot injury, applying Orthocell’s collagen-based nerve wrap designed to support and enhance the regeneration of damaged peripheral nerves.
Remplir’s US debut signals an important strategic foothold for Orthocell, opening doors to the world’s largest healthcare market. With the US nerve repair segment alone estimated to be worth around US$2.4 billion, the opportunity is significant. Orthocell is positioning Remplir as a clinically proven alternative in a space that sees approximately two million peripheral nerve procedures conducted each year.
Backed by a strong financial foundation—holding approximately A$30 million in cash and operating without debt—Orthocell is poised to accelerate Remplir's market penetration. In April 2025, the company engaged 14 specialist distributors across key US regions. The successful Ohio surgery was a direct outcome of one such distributor’s collaboration with a local surgeon, highlighting the effectiveness of this strategic expansion model.
Manufactured in Perth, Remplir offers surgeons a reliable and innovative tool to enhance patient outcomes in nerve repair. These early procedures serve a dual purpose—demonstrating efficacy while building surgeon familiarity and confidence, which will be essential in driving broader clinical adoption.
Looking ahead, Orthocell aims to strengthen its presence in both existing and new markets through its targeted commercial efforts. The company anticipates tangible growth in Remplir sales during the second half of calendar year 2025.
